Group 1 - Sight Sciences, Inc. reported a quarterly loss of 0.23pershare,whichwasworsethantheZacksConsensusEstimateofalossof0.20, and compared to a loss of 0.22pershareayearago,indicatinganearningssurpriseof−1519.07 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.50%, and showing an increase from 18.75millioninthesamequarterlastyear[2]−SightScienceshassurpassedconsensusEPSestimatestwotimesoverthelastfourquartersandtoppedconsensusrevenueestimatesthreetimesduringthesameperiod[2]Group2−Thestockhasunderperformed,losingabout32.10.23 on revenues of 19.11million,andforthecurrentfiscalyear,itis−0.91 on revenues of $82.27 million [7] - The Zacks Industry Rank for Medical - Instruments is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]